SCHEMBL7520977

SCHEMBL7520977

Cn1c(-c2ccc(/C=C3/SC(=O)NC3=O)cc2)nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 3/20 0.53
GAA P10253 3/20 0.53
SI P14410 3/20 0.53
MGAM2 Q2M2H8 3/20 0.53
IGF1R P08069 3/20 0.53
PIM1 P11309 5/20 0.48
PIM2 Q9P1W9 4/20 0.48
HPGD P15428 1/20 0.48
GLS O94925 2/20 0.46
GLS2 Q9UI32 2/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HTT P42858 1/20 0.45
CISD1 Q9NZ45 3/20 0.44
PIK3CD O00329 1/20 0.44
CSNK2A2 P19784 1/20 0.44
MAOB P27338 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
MTOR P42345 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7520980 1.00 MGAM (0.53) MGAMGAASIMGAM2IGF1R
SCHEMBL7519434 0.86 MGAM (0.55) MGAMGAASIMGAM2IGF1R
SCHEMBL7519438 0.86 MGAM (0.55) MGAMGAASIMGAM2IGF1R
SCHEMBL7556213 0.85 MGAM (0.55) MGAMGAASIMGAM2IGF1R
SCHEMBL7556207 0.85 MGAM (0.55) MGAMGAASIMGAM2IGF1R
SCHEMBL7509197 0.83 MGAM (0.60) MGAMGAASIMGAM2IGF1R
SCHEMBL7509203 0.83 MGAM (0.60) MGAMGAASIMGAM2IGF1R
SCHEMBL7517163 0.82 IGF1R (0.53) MGAMGAASIMGAM2IGF1R
SCHEMBL7515553 0.82 MGAM (0.56) MGAMGAASIMGAM2IGF1R
SCHEMBL7515220 0.82 MGAM (0.72) MGAMGAASIMGAM2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452014-B1 THIAZOLIDINEDIONE COMPOUNDS GERON CORPORATION 2002-09-17 US disclosed
US-20020120144-A1 Telomerase inhibitors and methods of their use KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-08-29 US disclosed
WO-2002051409-A1 TELOMERASE INHIBITORS AND METHODS OF THEIR USE GERON CORPORATION (US) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120144-A1 Telomerase inhibitors and methods of their use TERT, TERF2, POT1 MGAM 3441/4885GAA 625/4885SI 3172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.